hVIVO announces annual report and upcoming AGM

LONDON - hVIVO plc (AIM:HVO), a leading Contract Research Organisation specializing in human challenge clinical trials, has released its Annual Report and Accounts for the year ending December 31, 2024. The company also announced the scheduling of its Annual General Meeting (AGM) for June 5, 2025, at the offices of Cavendish Capital Markets Ltd in London.

The documents pertaining to the Annual Report and the notice of the AGM have been made available for shareholders to download from hVIVO’s website. The AGM will address standard procedural matters and also feature a directorate change.

The company disclosed that Martin Gouldstone, a Non-Executive Director who joined the board in June 2022, will not seek re-election and will step down following the AGM. Gouldstone is leaving to concentrate on other business ventures. hVIVO’s Nominations Committee has identified a new independent Non-Executive Director who is expected to bring valuable experience to the board, particularly in chairing the audit committee. This appointment is pending the customary due diligence by the company’s Nominated Adviser.

Additionally, hVIVO’s co-founder and Chair for the past eight years, Cathal Friel, has decided not to seek re-election at the upcoming AGM. Friel will remain in his role until the meeting concludes. Dr Elaine Sullivan, currently the Senior Independent (LON:IOG) Non-Executive Director, will serve as Interim Chair of the Board while the search for a new permanent Chair continues. The company will announce the outcome of this search when it is finalized.

The Board expressed its gratitude to both Cathal Friel and Martin Gouldstone for their significant contributions and leadership during their time with hVIVO.

This report is based on a press release statement and provides a factual account of the company’s announcements without any endorsement of claims.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.